NASDAQ : RXRX
Recursion Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 4.03 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.41B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.41B |
| Enterprise Value | 1.93B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 2, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 596.88M |
| Shares Outstanding | 597.81M |
| Shares Change (YoY) | +41.13% |
| Shares Change (QoQ) | +0.60% |
| Owned by Insiders (%) | 2.67% |
| Owned by Institutions (%) | 61.15% |
| Float | 580.95M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 44.14 |
| Forward PS | 41.96 |
| PB Ratio | 2.36 |
| P/TBV Ratio | 5.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 35.40 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.03 |
| Quick Ratio | 4.67 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -371.35 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -56.58% |
| Return on Assets (ROA) | -27.33% |
| Return on Invested Capital (ROIC) | -34.57% |
| Return on Capital Employed (ROCE) | -50.33% |
| Weighted Average Cost of Capital (WACC) | 9.71% |
| Revenue Per Employee | $91,427 |
| Profits Per Employee | -$864,807 |
| Employee Count | 600 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -4.58M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.03 |
| 52-Week Price Change | -26.99% |
| 50-Day Moving Average | 3.76 |
| 200-Day Moving Average | 3.52 |
| Relative Strength Index (RSI) | 52.59 |
| Average Volume (20 Days) | 28,239,401 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 161.93M |
| Short Previous Month | 157.94M |
| Short % of Shares Out | 27.09% |
| Short % of Float | 27.87% |
| Short Ratio (days to cover) | 5.28 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 54.86M |
| Gross Profit | -392.60M |
| Operating Income | -549.97M |
| Pretax Income | -523.47M |
| Net Income | -518.88M |
| EBITDA | -471.60M |
| EBIT | -549.97M |
| Loss Per Share | -$1.02 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 545.68M |
| Total Debt | 66.64M |
| Net Cash | 479.05M |
| Net Cash Per Share | $0.80 |
| Equity (Book Value) | 915.00M |
| Book Value Per Share | 1.71 |
| Working Capital | 483.58M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -350.48M |
| Capital Expenditures | -1.79M |
| Depreciation & Amortization | 78.36M |
| Net Borrowing | -8.75M |
| Free Cash Flow | -352.27M |
| FCF Per Share | -$0.59 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -1,002.56% |
| Pretax Margin | -954.25% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -41.13% |
| Shareholder Yield | -41.13% |
| Earnings Yield | -25.36% |
| FCF Yield | -14.55% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $7.32 |
| Price Target Difference | 81.56% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 19.15% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.61 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |